Barve M, Aaron P, Manning L, Bognar E, et al. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. Clin Med Insights Oncol 2022;16:11795549221110501.
PMID: 35957960